← Back to Screener
Celldex Therapeutics, Inc (CLDX)
Price$34.38
Favorite Metrics
Price vs S&P 500 (26W)20.32%
Price vs S&P 500 (4W)2.32%
Market Capitalization$2.71B
All Metrics
Book Value / Share (Quarterly)$7.92
P/TBV (Annual)3.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-13.17%
Cash Flow / Share (Quarterly)$-3.21
Price vs S&P 500 (YTD)23.07%
Gross Margin (TTM)17.65%
Net Profit Margin (TTM)-12400.58%
EPS (TTM)$-3.90
10-Day Avg Trading Volume1.19M
EPS Excl Extra (TTM)$-3.90
Revenue Growth (5Y)-26.94%
EPS (Annual)$-3.90
ROI (Annual)-49.08%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-5465.53%
Cash / Share (Quarterly)$7.79
Revenue Growth QoQ (YoY)-89.70%
ROA (Last FY)-44.38%
Revenue Growth TTM (YoY)-77.98%
EBITD / Share (TTM)$-4.28
ROE (5Y Avg)-30.88%
Operating Margin (TTM)-13825.94%
Cash Flow / Share (Annual)$-3.21
P/B Ratio5.14x
P/B Ratio (Quarterly)3.42x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1734.82x
Net Interest Coverage (TTM)-740.36x
ROA (TTM)-38.86%
EPS Incl Extra (Annual)$-3.90
Current Ratio (Annual)10.49x
Quick Ratio (Quarterly)10.21x
3-Month Avg Trading Volume0.94M
52-Week Price Return94.10%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.51
P/S Ratio (Annual)1754.63x
Asset Turnover (Annual)0.00x
52-Week High$35.29
Operating Margin (5Y Avg)-6007.73%
EPS Excl Extra (Annual)$-3.90
CapEx CAGR (5Y)11.86%
Tangible BV CAGR (5Y)22.86%
26-Week Price Return29.06%
Quick Ratio (Annual)10.21x
13-Week Price Return31.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.49x
Enterprise Value$2,682.029
Revenue / Share Growth (5Y)-37.80%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)8.43%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.80x
Pretax Margin (Annual)-16748.03%
Cash / Share (Annual)$7.79
3-Month Return Std Dev66.18%
Gross Margin (5Y Avg)44.59%
Net Income / Employee (TTM)$-1
ROE (Last FY)-49.08%
Net Interest Coverage (Annual)-55.51x
EPS Basic Excl Extra (Annual)$-3.90
P/FCF (TTM)87.06x
Receivables Turnover (TTM)1.14x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.90
Receivables Turnover (Annual)1.14x
ROI (TTM)-41.67%
P/S Ratio (TTM)1753.49x
Pretax Margin (5Y Avg)-5466.52%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$7.51
Price vs S&P 500 (52W)59.01%
Year-to-Date Return27.21%
5-Day Price Return6.01%
EPS Normalized (Annual)$-3.90
ROA (5Y Avg)-28.48%
Net Profit Margin (Annual)-16748.03%
Month-to-Date Return8.92%
Cash Flow / Share (TTM)$-2.58
EBITD / Share (Annual)$-4.28
Operating Margin (Annual)-18599.81%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-30.88%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.90
P/TBV (Quarterly)3.61x
P/B Ratio (Annual)3.42x
Inventory Turnover (TTM)0.80x
Pretax Margin (TTM)-12400.58%
Book Value / Share (Annual)$7.92
Price vs S&P 500 (13W)28.30%
Beta1.01x
P/FCF (Annual)159.65x
Revenue / Share (TTM)$0.02
ROE (TTM)-41.67%
52-Week Low$17.45
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.05
4.05
4.05
4.14
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CLDXCelldex Therapeutics, Inc | 1753.49x | -77.98% | 17.65% | — | $34.38 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 295.25x | -5.72% | 89.00% | — | $26.98 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.21 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.99 |
About
Celldex Therapeutics develops monoclonal and bispecific antibodies to treat mast cell-mediated inflammatory, allergic, and autoimmune diseases. The company combines research in mast cell biology with manufacturing and commercialization capabilities to advance its therapeutic pipeline.